Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).
Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, Davey VJ, Gelijns AC, Ginde AA, Grund B, Higgs E, Hudson F, Kan VL, Lane HC, Murray TA, Paredes R, Parmar MK, Pett S, Phillips AN, Polizzotto MN, Reilly C, Sandkovsky U, Sharma S, Teitelbaum M, Thompson BT, Young BE, Neaton JD, Lundgren JD. Murray DD, et al. Among authors: young be. Clin Trials. 2022 Feb;19(1):52-61. doi: 10.1177/17407745211049829. Epub 2021 Oct 10. Clin Trials. 2022. PMID: 34632800 Free PMC article.
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).
Murray DD, Babiker AG, Baker JV, Barkauskas CE, Brown SM, Chang CC, Davey VJ, Gelijns AC, Ginde AA, Grund B, Higgs E, Hudson F, Kan VL, Lane HC, Murray TA, Paredes R, Parmar MKB, Pett S, Phillips AN, Polizzotto MN, Reilly C, Sandkovsky U, Sharma S, Teitelbaum M, Thompson BT, Young BE, Neaton JD, Lundgren JD. Murray DD, et al. Among authors: young be. medRxiv [Preprint]. 2021 Apr 8:2020.11.08.20227876. doi: 10.1101/2020.11.08.20227876. medRxiv. 2021. Update in: Clin Trials. 2022 Feb;19(1):52-61. doi: 10.1177/17407745211049829 PMID: 33215168 Free PMC article. Updated. Preprint.
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Kalil AC, et al. N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11. N Engl J Med. 2021. PMID: 33306283 Free PMC article. Clinical Trial.
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
ACTIV-3/TICO LY-CoV555 Study Group; Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Davey VJ, Goodman A, Higgs ES, Murray DD, Murray TA, Paredes R, Parmar MKB, Phillips AN, Reilly C, Sharma S, Dewar RL, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. ACTIV-3/TICO LY-CoV555 Study Group, et al. N Engl J Med. 2021 Mar 11;384(10):905-914. doi: 10.1056/NEJMoa2033130. Epub 2020 Dec 22. N Engl J Med. 2021. PMID: 33356051 Free PMC article. Clinical Trial.
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
ACTIV-3/TICO Bamlanivimab Study Group; Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. ACTIV-3/TICO Bamlanivimab Study Group, et al. Ann Intern Med. 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507. Epub 2021 Dec 21. Ann Intern Med. 2022. PMID: 34928698 Free PMC article. Clinical Trial.
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9. Epub 2021 Dec 23. Lancet Infect Dis. 2022. PMID: 34953520 Free PMC article. Clinical Trial.
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.
Douin DJ, Siegel L, Grandits G, Phillips A, Aggarwal NR, Baker J, Brown SM, Chang CC, Goodman AL, Grund B, Higgs ES, Hough CL, Murray DD, Paredes R, Parmar M, Pett S, Polizzotto MN, Sandkovsky U, Self WH, Young BE, Babiker AG, Davey VJ, Kan V, Gelijns AC, Matthews G, Thompson BT, Lane HC, Neaton JD, Lundgren JD, Ginde AA. Douin DJ, et al. Among authors: young be. Am J Respir Crit Care Med. 2022 Sep 15;206(6):730-739. doi: 10.1164/rccm.202112-2836OC. Am J Respir Crit Care Med. 2022. PMID: 35580040 Free PMC article.
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY, Lee IR, Lim C, Teo J, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Ng LFP, Ren EC, Lin RTP, Wang LF, Renia L, Lye DC, Young BE. Poh XY, et al. Among authors: young be. Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2. Trials. 2022. PMID: 35710572 Free PMC article.
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
ACTIV-3/TICO Study Group; Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM, Rogers R, Shehadeh F, Kaczynski M, Mylona EK, Syrigos KN, Rapti V, Lye DC, Hui DS, Leither L, Knowlton KU, Jain MK, Marines-Price R, Osuji A, Overcash JS, Kalomenidis I, Barmparessou Z, Waters M, Zepeda K, Chen P, Torbati S, Kiweewa F, Sebudde N, Almasri E, Hughes A, Bhagani SR, Rodger A, Sandkovsky U, Gottlieb RL, Nnakelu E, Trautner B, Menon V, Lutaakome J, Matthay M, Robinson P, Protopapas K, Koulouris N, Kimuli I, Baduashvili A, Braun DL, Günthard HF, Ramachandruni S, Kidega R, Kim K, Hatlen TJ, Phillips AN, Murray DD, Jensen TO, Padilla ML, Accardi EX, Shaw-Saliba K, Dewar RL, Teitelbaum M, Natarajan V, Laverdure S, Highbarger HC, Rehman MT, Vogel S, Vallée D, Crew P, Atri N, Schechner AJ, Pett S, Hudson F, Badrock J, Touloumi G, Brown SM, Self WH, North CM, Ginde AA, Chang CC, Kelleher A, Nagy-Agren S, Vasudeva S, Looney D, Nguyen HH, Sánchez A, Weintrob AC, Grund B, Sharma S, Reilly CS, Paredes R, Bednarska A, Gerry NP, Babiker AG, Davey VJ, Gelijns AC, Higgs ES, Kan V, Matthews G, Thompson BT, Legenne P, Chandra R, Lane HC, Neato… See abstract for full author list ➔ ACTIV-3/TICO Study Group, et al. Among authors: young be. Ann Intern Med. 2022 Sep;175(9):1266-1274. doi: 10.7326/M22-1503. Epub 2022 Aug 9. Ann Intern Med. 2022. PMID: 35939810 Free PMC article. Clinical Trial.
269 results